Orient EuroPharma Statistics

Total Valuation

Orient EuroPharma has a market cap or net worth of TWD 4.19 billion. The enterprise value is 7.99 billion.

Market Cap	4.19B
Enterprise Value	7.99B

Important Dates

The last earnings date was Friday, November 8, 2024.

Earnings Date	Nov 8, 2024
Ex-Dividend Date	n/a

Share Statistics

Orient EuroPharma has 86.75 million shares outstanding. The number of shares has increased by 0.14% in one year.

Current Share Class	n/a
Shares Outstanding	86.75M
Shares Change (YoY)	+0.14%
Shares Change (QoQ)	+0.88%
Owned by Insiders (%)	13.80%
Owned by Institutions (%)	1.36%
Float	55.70M

Valuation Ratios

The trailing PE ratio is 21.91.

PE Ratio	21.91
Forward PE	n/a
PS Ratio	0.94
PB Ratio	0.81
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 27.39, with an EV/FCF ratio of -311.92.

EV / Earnings	41.87
EV / Sales	1.79
EV / EBITDA	27.39
EV / EBIT	98.96
EV / FCF	-311.92

Financial Position

The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.85.

Current Ratio	0.98
Quick Ratio	0.67
Debt / Equity	0.85
Debt / EBITDA	15.68
Debt / FCF	-194.13
Interest Coverage	0.98

Financial Efficiency

Return on equity (ROE) is 5.07% and return on invested capital (ROIC) is 0.65%.

Return on Equity (ROE)	5.07%
Return on Assets (ROA)	0.56%
Return on Capital (ROIC)	0.65%
Revenue Per Employee	13.19M
Profits Per Employee	563,145
Employee Count	339
Asset Turnover	0.38
Inventory Turnover	2.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +24.26% in the last 52 weeks. The beta is 0.41, so Orient EuroPharma's price volatility has been lower than the market average.

Beta (5Y)	0.41
52-Week Price Change	+24.26%
50-Day Moving Average	49.18
200-Day Moving Average	45.31
Relative Strength Index (RSI)	40.51
Average Volume (20 Days)	62,087

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Orient EuroPharma had revenue of TWD 4.47 billion and earned 190.91 million in profits. Earnings per share was 2.20.

Revenue	4.47B
Gross Profit	2.17B
Operating Income	106.18M
Pretax Income	415.69M
Net Income	190.91M
EBITDA	304.71M
EBIT	106.18M
Earnings Per Share (EPS)	2.20

Full Income Statement

Balance Sheet

The company has 1.82 billion in cash and 4.98 billion in debt, giving a net cash position of -3.15 billion or -36.33 per share.

Cash & Cash Equivalents	1.82B
Total Debt	4.98B
Net Cash	-3.15B
Net Cash Per Share	-36.33
Equity (Book Value)	5.88B
Book Value Per Share	59.67
Working Capital	-61.59M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 42.32 million and capital expenditures -67.94 million, giving a free cash flow of -25.63 million.

Operating Cash Flow	42.32M
Capital Expenditures	-67.94M
Free Cash Flow	-25.63M
FCF Per Share	-0.30

Full Cash Flow Statement

Margins

Gross margin is 48.44%, with operating and profit margins of 2.37% and 4.27%.

Gross Margin	48.44%
Operating Margin	2.37%
Pretax Margin	9.30%
Profit Margin	4.27%
EBITDA Margin	6.82%
EBIT Margin	2.37%
FCF Margin	-0.57%

Dividends & Yields

This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 2.07%.

Dividend Per Share	1.00
Dividend Yield	2.07%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	45.44%
Buyback Yield	-0.14%
Shareholder Yield	1.93%
Earnings Yield	4.57%
FCF Yield	-0.61%

Dividend Details

Stock Splits

The last stock split was on July 28, 2010. It was a forward split with a ratio of 1.16.

Last Split Date	Jul 28, 2010
Split Type	Forward
Split Ratio	1.16

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a